MeiraGTx Holdings plc SEC 10-Q Report

MeiraGTx Holdings plc, a clinical-stage gene therapy company, has released its Form 10-Q report for the third quarter, providing insights into its financial and operational performance. The report highlights the company's progress in service revenue growth, operational cost management, and strategic collaborations, reflecting its ongoing efforts in the gene therapy industry.

Financial Highlights

• Service revenue - related party: $1.926 million, increased from $0.697 million in the prior year period, reflecting growth in service activities.
• Loss from operations: $(41.596) million, improved from $(46.772) million in the prior year period, indicating a reduction in operating expenses.
• Net loss: $(39.981) million, compared to $(20.442) million in the prior year period, primarily due to the absence of a gain on sale of nonfinancial assets.
• Basic and diluted net loss per ordinary share: $(0.51), compared to $(0.32) in the prior year period, reflecting the increased net loss.

Business Highlights

• Revenue Segments: The company reported service revenue from related parties, primarily driven by process performance qualification (PPQ) services under the Asset Purchase Agreement with Johnson & Johnson Innovative Medicine.
• Geographical Performance: The company's service revenue and deferred revenue from the Asset Purchase Agreement and related agreements were generated in the United Kingdom, indicating a strong regional focus.
• Sales Units: The company highlighted the ongoing manufacturing and supply of the RPGR Product for Johnson & Johnson Innovative Medicine.
• Future Outlook: The company anticipates the closing of a strategic collaboration with Hologen Limited, which is expected to provide significant funding and support for the development of its clinical programs and manufacturing capabilities.

SEC Filing: MeiraGTx Holdings plc [ MGTX ] - 10-Q - May. 13, 2025